Daily Endocrinology Research Analysis
Three impactful endocrinology papers stood out today: a multi-omics study identified circulating microbial-associated uremic toxins as high-accuracy biomarkers for metastatic duodenopancreatic NETs in MEN1; a newborn screening cohort linked C26:0-lysophosphatidylcholine to phenotype in adrenoleukodystrophy, informing risk-adapted surveillance; and a nationwide cohort suggested GLP-1 receptor agonists lower knee osteoarthritis and total knee replacement risk in type 2 diabetes.
Summary
Three impactful endocrinology papers stood out today: a multi-omics study identified circulating microbial-associated uremic toxins as high-accuracy biomarkers for metastatic duodenopancreatic NETs in MEN1; a newborn screening cohort linked C26:0-lysophosphatidylcholine to phenotype in adrenoleukodystrophy, informing risk-adapted surveillance; and a nationwide cohort suggested GLP-1 receptor agonists lower knee osteoarthritis and total knee replacement risk in type 2 diabetes.
Research Themes
- Translational biomarkers in endocrine oncology
- Risk stratification from newborn screening biomarkers
- Cardiometabolic therapies with musculoskeletal benefits
Selected Articles
1. Elevated levels of circulating microbial-associated uremic toxins are associated with metastatic duodenopancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia Type 1.
In MEN1, circulating microbial-associated uremic toxins (e.g., TMAO, indoxyl sulfate) were elevated in patients with metastatic dpNETs and correlated with microbial peptide signatures in tumor tissue. A multi-marker panel achieved an AUC of 0.94 (67% sensitivity at 95% specificity) in an independent validation cohort, and early increases associated with worse survival in a Men1 model.
Impact: This work proposes a blood-based, microbiome-linked biomarker panel for identifying metastatic dpNETs in MEN1 with high diagnostic accuracy, potentially transforming surveillance strategies.
Clinical Implications: A validated uremic toxin panel could help prioritize imaging and intensify follow-up for MEN1 patients at high risk of metastasis, enabling earlier interventions.
Key Findings
- Circulating TMAO, indoxyl sulfate, cresol sulfate, cresol glucuronide, and phenol sulfate were elevated in MEN1 patients with metastatic dpNETs.
- A microbial-associated uremic toxin panel (MUTP) achieved AUC 0.94 (95% CI 0.85–1.00), 67% sensitivity at 95% specificity in an independent validation cohort.
- Tumor proteomic/metabolomic profiles correlated with bacterial peptide signatures (e.g., F. nucleatum, F. prausnitzii, K. pneumoniae) and uremic toxin levels; early toxin increases associated with poorer survival in a Men1 model.
Methodological Strengths
- Multi-omics integration (proteomics and metabolomics) linked to circulating biomarkers
- Independent case-control validation with strong diagnostic performance (AUC 0.94)
Limitations
- Exact cohort sizes and multicenter generalizability are not specified in the abstract
- Causality between microbial signatures and metastasis cannot be inferred from observational data
Future Directions: Prospective, multicenter validation and assessment of clinical utility (e.g., risk-adapted imaging schedules) and mechanistic studies to disentangle microbiome–tumor interactions.
Metastatic duodenopancreatic neuroendocrine tumors (dpNETs) are the primary cause of mortality among patients with Multiple Endocrine Neoplasia Type 1 (MEN1). Emerging evidence implicates the microbiome and microbial-derived secreted factors in promoting cancer development and progression. In the current study, we report that the circulating microbial-associated uremic toxins trimethylamine N-oxide (TMAO), indoxyl sulfate (IS), cresol sulfate (CS), cresol glucuronide (CG), and phenol sulfate (PS) are elevated in MEN1 patients with metastatic dpNETs. Proteomic- and metabolomic-based analysis of resected dpNET tissues from MEN1 patients also revealed detectable levels of uremic toxins that positively correlated with peptide-based signatures corresponding to Fusobacterium nucleatum, Faecalibacterium prausnitzii, and Klebsiella pneumoniae and negatively correlated with Streptococcus pneumoniae and Streptococcus thermophilus. A microbial-associated uremic toxin panel (MUTP) was developed and, in an independent case-control validation cohort, the panel yielded an area under the receiver operating characteristic curve (AUC) of 0.94 (95 % CI: 0.85-1.00) with 67 % sensitivity at 95 % specificity for identifying MEN1 patients with metastatic dpNETS. Increases in circulating microbial-associated uremic toxins during early stages of neoplasia were also found to be associated with poor overall survival in an Men1
2. Prognostication and Biomarker Potential of C26:0 Lysophosphatidylcholine in Adrenoleukodystrophy.
In a newborn-screened ALD cohort with 5-year follow-up, C26:0-LPC levels correlated with clinical phenotype, supporting its role as a prognostic biomarker. The authors recommend modifying early childhood surveillance intensity for children with lower C26:0-LPC to avoid over-surveillance.
Impact: Provides actionable, biomarker-driven risk stratification to personalize surveillance in ALD detected by newborn screening.
Clinical Implications: C26:0-LPC can guide surveillance frequency in early childhood ALD, potentially reducing unnecessary procedures while focusing resources on higher-risk children.
Key Findings
- C26:0-LPC levels correlated with ALD clinical phenotype over a 5-year follow-up.
- Data support reducing surveillance intensity in early childhood for children with lower C26:0-LPC.
- Findings were derived from a newborn-screened state-wide cohort, enhancing real-world applicability.
Methodological Strengths
- Prospective cohort derived from newborn screening with 5-year longitudinal follow-up
- Clear, clinically actionable recommendation based on biomarker–phenotype correlation
Limitations
- Sample size and detailed stratified analyses are not specified in the abstract
- Generalizability beyond a single state program needs multicenter validation
Future Directions: Multicenter validation of C26:0-LPC thresholds and integration into standardized surveillance protocols; cost-effectiveness analyses of risk-adapted surveillance.
This cohort study conducted among Minnesota children diagnosed with adrenoleukodystrophy through newborn screening examines correlation of C26:0 lysophosphatidylcholine (C26LPC) with clinical phenotype over 5 years and recommends adjusting early childhood surveillance regimens in children with lower C26LPC levels.
3. Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study.
In a Taiwan nationwide claims cohort (n=35,762) with propensity score matching and up to 5-year follow-up, GLP-1RA use was associated with reduced risks of knee osteoarthritis (adjusted HR 0.852, 95% CI 0.784–0.930) and total knee replacement (adjusted HR 0.913, 95% CI 0.885–0.977). Kaplan–Meier curves showed significantly lower cumulative incidence in GLP-1RA users.
Impact: Suggests a musculoskeletal benefit of GLP-1RA beyond glycemic control, a timely finding with high translational potential amidst widespread GLP-1RA use.
Clinical Implications: When selecting anti-hyperglycemic therapy for T2DM, potential KOA/TKR risk reduction may be an added consideration favoring GLP-1RAs, pending confirmatory prospective trials.
Key Findings
- Nationwide cohort (n=35,762) with 1:1 propensity matching and up to 5-year follow-up.
- GLP-1RA use associated with lower KOA risk (adjusted HR 0.852, 95% CI 0.784–0.930; P<.001).
- GLP-1RA use associated with lower TKR risk (adjusted HR 0.913, 95% CI 0.885–0.977; P=.015); log-rank P<.001 for both outcomes.
Methodological Strengths
- Large, population-based dataset with propensity score matching
- Time-to-event analyses (Cox models and Kaplan–Meier) with up to 5-year follow-up
Limitations
- Observational claims data subject to residual confounding and misclassification
- Indication bias and lifestyle factors not fully captured
Future Directions: Prospective RCTs or quasi-experimental studies to confirm causality; mechanistic studies on GLP-1RA effects on joint inflammation and cartilage metabolism.
Type 2 diabetes mellitus (T2DM) is an independent risk factor of knee osteoarthritis (KOA). This study was mainly based on data from the Taiwan National Health Insurance Database. Using big data analysis, we showed that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment is helpful for patients with T2DM who have a lower risk of KOA or total knee replacement (TKR). A total of 35,762 patients with T2DM were included in this study. We divided these patients into 988 patients with T2DM without KOA and 372 patients with T2DM with KOA who received GLP-1RA treatment and those who did not receive GLP-1RA treatment. The patients were matched for sex, age, and inclusion date by 1:1 propensity score, which was included in the control group. Cox proportional hazards analyses were performed to compare KOA risk and TKR rate during a maximum follow-up period of 5 years. There were 1976/744 patients with T2DM without/with KOA who received and did not receive GLP-1RA treatment, including 1052/322 men (53.24/43.28%) and 924/422 women (46.76/56.72%). At the end of follow-up, there were 46/39 (4.66/10.48%) patients with T2DM without/with KOA who received GLP-1RA treatment and underwent KOA/TKR were lower than those without GLP-1RA treatment 87/70 (8.81/18.82%). Cox proportional hazard regression analysis showed a lower rate of KOA/TKR among patients with GLP-1RA treatment (adjusted hazard ratio [HR] = .852; 95% confidence interval [CI] = .784-.930, P < .001/ adjusted HR = .913; 95% CI = .885-.977, P = .015, respectively). Kaplan-Meier analysis showed that the cumulative risk of KOA/TKR in patient with/without GLP-1RA was significantly different (log-rank test, P < .001/P < .001, respectively). This study aimed to provide clinicians with the option of GLP-1RA as a treatment for patients with T2DM with or without KOA to reduce the risk of KOA or TKR among such patients.